脾氨肽口服溶液联合常规用药治疗季节性变应性鼻炎伴随哮喘成人患者的成本-效果  

Cost-effectiveness of Spleen Aminopeptide Oral Solution combined with Conventional Medication in the Treatment of Adult Patients with Seasonal Allergic Rhinitis associated with Asthma

作　　者：孙权 张方 李明如 扶春阳 陈瀚翔 曾帅 马婷婷 SUN Quan;ZHANG Fang;LI Ming-Ru;FU Chun-Yang;CHEN Han-Xiang;ZENG Shuai;MA Ting-Ting(Health Care Security and Pharmacoeconomic Evaluation Branch of China Medical Education Association,Beijing,100071,China;Hainan Zhongwei Institute of Health Economy Development,Haikou 570106,China;School of Business Administration,Shenyang Pharmaceutical University Shenyang 110016,China;School of Public Health,Dalian Medical University,Dalian 116041,China;Allergy Department of Beijing Millennium Temple Hospital,Capital Medical University,Beijing 100038,China)

机构地区：[1]中国医药教育协会医疗保障与药物经济学评价分会 [2]海南中卫健康经济发展研究院 [3]沈阳药科大学工商管理学院 [4]大连医科大学公共卫生学院 [5]首都医科大学附属北京世纪坛医院变态反应科

出　　处：《中国药物经济学》2024年第12期11-19,24,共10页China Journal of Pharmaceutical Economics

摘　　要：目的基于医疗卫生体系角度,评价脾氨肽口服溶液联合常规治疗方案相比于仅使用常规治疗方案用于治疗中国季节性过敏性鼻炎(SAR)伴随哮喘成人患者的经济性。方法基于随访调查研究数据对两方案的疗效进行评价。构建Markov模型,估计两种方案的患者全生命周期成本和健康获益,进行成本-效果分析,并对基础分析结果进行敏感性分析和情景分析。结果相比仅使用常规治疗方案,脾氨肽口服溶液联合常规治疗方案可以有效控制SAR症状,提高中重度SAR患者的缓解率,并降低因SAR引发哮喘的风险,临床效果更优。脾氨肽口服溶液联合常规治疗方案对于SAR伴随哮喘患者的增量成本-效果比(ICER)为73805.55元/QALY,低于意愿支付(WTP)阈值(89358.00元),是具有成本-效果优势的用药方案。单因素敏感性分析和概率敏感性分析验证了模型的稳健性。用药10~50年的情景分析结果显示,在常规治疗方案基础上加用脾氨肽口服溶液的经济性会随着用药时间延长而愈发突出。结论对于中国SAR伴随哮喘患者,脾氨肽口服溶液联合常规治疗方案是临床获益明显,且具有成本-效果的长期用药选择。Objective From the perspective of the healthcare system,this study evaluates the economic impact of the combination of spleen aminopeptide oral solutionn with conventional therapy compared to conventional therapy alone for the treatment of adult patients with seasonal allergic rhinitis(SAR)accompanied by asthma in China.Methods The efficacy of the two treatment regimens was evaluated based on follow-up survey and research data.A Markov model was constructed to estimate the full life-cycle costs and health benefits of the two regimens.A cost-effectiveness analysis was conducted,and sensitivity analysis and scenario analysis were performed on the basic analysis results.Results Compared with conventional therapy alone,the combination of spleen aminopeptide oral solution with conventional therapy effectively controlled SAR symptoms,improved the remission rate among patients with moderate-to-severe SAR,and reduced the risk of asthma triggered by SAR,demonstrating superior clinical outcomes.The incremental cost-effectiveness ratio(ICER)of the combination therapy for SAR patients with asthma was 73805.55 Chinese yuan per quality-adjusted life year(QALY),which was lower than the willingness-to-pay(WTP)threshold of 89358.00 Chinese yuan.This indicates that the combination therapy is a cost-effective medication option.One-way sensitivity analysis and probabilistic sensitivity analysis verified the robustness of the model.Scenario analysis results for medication use over 10 to 50 years showed that the economic benefit of adding splenopeptide oral solution to conventional therapy became increasingly prominent as the duration of medication use increased.Conclusion For Chinese patients with SAR accompanied by asthma,the combination of spleen aminopeptide oral solution with conventional therapy is a clinically beneficial and cost-effective long-term medication option with significant clinical gains.

关 键 词：脾氨肽口服溶液 季节性变应性鼻炎 哮喘 成本-效果分析 

分 类 号：R765.21[医药卫生—耳鼻咽喉科] R956[医药卫生—临床医学]